Management of Post-COVID-19-Related Olfactory Dysfunction

Detalhes bibliográficos
Autor(a) principal: Gomes,Catarina Castro
Data de Publicação: 2022
Outros Autores: Soutinho,Joana, Pereira,Ana Luísa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221
Resumo: Abstract Evidence suggests that the prevalence of olfactory dysfunction (OD) occurs in 50% of patients with COVID-19. Emerging data suggest a high rate of early and spontaneous recovery, but approximately 10% of patients showed no improvement at 4-6 weeks after recovery. Given the high prevalence of COVID-19, a considerable number of patients will experience this morbidity. Thus, the main goal of this review is to define a guideline protocol for patients recovered from COVID-19, who present with olfactory dysfunction. In those cases, it is important to start by classifying the severity of this change and rule out other possible underlying etiologies, which may require further investigation. The treatment with best results is olfactory training. Additionally, the use of nasal corticosteroid spray or omega-3 supplementation may be recommended. It should be noted that those conclusions are based upon clinical trials whose patients were infected by viruses other than SARS-CoV-2. This way, further study and validation regarding the treatment of this condition should be carried out as the pandemic progresses.
id RCAP_e3c75d51f9423e90a27d5cba3cc6a8ba
oai_identifier_str oai:scielo:S2184-06282022000300221
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Management of Post-COVID-19-Related Olfactory DysfunctionCOVID-19/complicationsOlfaction Disorders/drug therapyOlfaction Disorders/etiologyAbstract Evidence suggests that the prevalence of olfactory dysfunction (OD) occurs in 50% of patients with COVID-19. Emerging data suggest a high rate of early and spontaneous recovery, but approximately 10% of patients showed no improvement at 4-6 weeks after recovery. Given the high prevalence of COVID-19, a considerable number of patients will experience this morbidity. Thus, the main goal of this review is to define a guideline protocol for patients recovered from COVID-19, who present with olfactory dysfunction. In those cases, it is important to start by classifying the severity of this change and rule out other possible underlying etiologies, which may require further investigation. The treatment with best results is olfactory training. Additionally, the use of nasal corticosteroid spray or omega-3 supplementation may be recommended. It should be noted that those conclusions are based upon clinical trials whose patients were infected by viruses other than SARS-CoV-2. This way, further study and validation regarding the treatment of this condition should be carried out as the pandemic progresses.Círculo Médico2022-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221Gazeta Médica v.9 n.3 2022reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221Gomes,Catarina CastroSoutinho,JoanaPereira,Ana Luísainfo:eu-repo/semantics/openAccess2024-02-06T17:32:17Zoai:scielo:S2184-06282022000300221Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:35:05.601442Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Management of Post-COVID-19-Related Olfactory Dysfunction
title Management of Post-COVID-19-Related Olfactory Dysfunction
spellingShingle Management of Post-COVID-19-Related Olfactory Dysfunction
Gomes,Catarina Castro
COVID-19/complications
Olfaction Disorders/drug therapy
Olfaction Disorders/etiology
title_short Management of Post-COVID-19-Related Olfactory Dysfunction
title_full Management of Post-COVID-19-Related Olfactory Dysfunction
title_fullStr Management of Post-COVID-19-Related Olfactory Dysfunction
title_full_unstemmed Management of Post-COVID-19-Related Olfactory Dysfunction
title_sort Management of Post-COVID-19-Related Olfactory Dysfunction
author Gomes,Catarina Castro
author_facet Gomes,Catarina Castro
Soutinho,Joana
Pereira,Ana Luísa
author_role author
author2 Soutinho,Joana
Pereira,Ana Luísa
author2_role author
author
dc.contributor.author.fl_str_mv Gomes,Catarina Castro
Soutinho,Joana
Pereira,Ana Luísa
dc.subject.por.fl_str_mv COVID-19/complications
Olfaction Disorders/drug therapy
Olfaction Disorders/etiology
topic COVID-19/complications
Olfaction Disorders/drug therapy
Olfaction Disorders/etiology
description Abstract Evidence suggests that the prevalence of olfactory dysfunction (OD) occurs in 50% of patients with COVID-19. Emerging data suggest a high rate of early and spontaneous recovery, but approximately 10% of patients showed no improvement at 4-6 weeks after recovery. Given the high prevalence of COVID-19, a considerable number of patients will experience this morbidity. Thus, the main goal of this review is to define a guideline protocol for patients recovered from COVID-19, who present with olfactory dysfunction. In those cases, it is important to start by classifying the severity of this change and rule out other possible underlying etiologies, which may require further investigation. The treatment with best results is olfactory training. Additionally, the use of nasal corticosteroid spray or omega-3 supplementation may be recommended. It should be noted that those conclusions are based upon clinical trials whose patients were infected by viruses other than SARS-CoV-2. This way, further study and validation regarding the treatment of this condition should be carried out as the pandemic progresses.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Círculo Médico
publisher.none.fl_str_mv Círculo Médico
dc.source.none.fl_str_mv Gazeta Médica v.9 n.3 2022
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137405604724736